Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Farletuzumab MMAE

Copy Product Info
😃Good
Catalog No. T9901A-207

Farletuzumab-MMAE, an antibody-drug conjugate (ADC), combines an FRA-targeted antibody with Monomethyl auristatin E (MMAE) and is utilized in researching non-small cell lung cancer.

Farletuzumab MMAE

Farletuzumab MMAE

Copy Product Info
😃Good
Catalog No. T9901A-207
Farletuzumab-MMAE, an antibody-drug conjugate (ADC), combines an FRA-targeted antibody with Monomethyl auristatin E (MMAE) and is utilized in researching non-small cell lung cancer.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Farletuzumab-MMAE, an antibody-drug conjugate (ADC), combines an FRA-targeted antibody with Monomethyl auristatin E (MMAE) and is utilized in researching non-small cell lung cancer.
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
MMAE
Antigen Details
Uniprot ID
TargetFRA
Chemical Properties
Molecular Weight150.62 kDa
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storage-20°C for 1 year | Shipping with blue ice.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Farletuzumab MMAE | purchase Farletuzumab MMAE | Farletuzumab MMAE cost | order Farletuzumab MMAE | Farletuzumab MMAE molecular weight